contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


presentation-of-zerion-pharma-by-ceo-ole-viborg-and-cfo-jakob-dynes-hansen

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

CEO, Sweden

Claus Thestrup

Zerion Pharma

Zerion Pharma is a non-listed Danish company seeking €2-3m in a private placement round.

Management will briefly run through the investment proposal and business case. Then management will focus on the regulatory environment governing the Dispersome™ technology, formulation of new drugs, and reformulation of existing drugs.
Last but not least CEO Ole Wiborg will give a little flavor on the company’s strategic partnerships.

Zerion Pharma is a non-listed Danish company seeking &euro;2-3m in a private placement round.
Terms:
Closing date 15th. of March 2023, Lot size &euro; 33t and pre-money valuation &euro; 14m.
Contact: CEO Ole Wiborg -&nbsp;ow@zerion.eu&nbsp;or CFO Jakob Dynnes Hansen -&nbsp;jdh@zerion.eu&nbsp;if you are interested to subscribe and further details.
In the first interview, management will run through the investment proposal and business case. This is a general introduction to the case:
Watch here: <a href="https://www.inderes.dk/en/videos/zerion-pharma-company-introduction">https://www.inderes.dk/en/videos/zerion-pharma-company-introduction</a>
In the second interview,&nbsp;management will focus on the regulatory environment governing the Dispersome&trade; technology, formulation of new drugs, and reformulation of existing drugs. Last but not least CEO Ole Wiborg will give a little flavor on the company&rsquo;s strategic partnerships.
Watch here: <a href="https://www.inderes.dk/en/videos/zerion-pharma-regulatory-environment-and-strategic-partnerships">https://www.inderes.dk/en/videos/zerion-pharma-regulatory-environment-and-strategic-partnerships</a>
Disclaimer: HC Andersen Capital receives payment from Zerion Pharma for a Digital IR/Corporate Visibility agreement. Zerion Pharma is a private company and is not listed on a regulated stock market. Investors should therefore be aware of the potential risks that can be associated with investing in a private company, including liquidity conditions, how shares are traded as well as the process of the specific capital raise.

HC Andersen Capital

Presentation of Zerion Pharma by CEO Ole Viborg and CFO Jakob Dynes Hansen

USA:s Black Week ledde till överraskande inköp

Uppgångsvecka bakom oss, Tyskland gick vidare med sin megabudget

Finlands ekonomiska tillväxt: ”Varje dag och varje natt tänker jag på dig”

Nedgångsvecka bakom oss, AI-oron når även obligationsmarknaden

USA:s sysselsättningssiffror: En ljusglimt i Feds fyr

Login required